Literature DB >> 7545579

Bone mineralisation in type 1 glycogen storage disease.

P J Lee1, J S Patel, M Fewtrell, J V Leonard, N J Bishop.   

Abstract

UNLABELLED: Radial bone mineral content (BMC) was measured using single photon absorptiometry in 11 prepubertal children, aged 3.4-12.6 years, with glycogen storage disease type 1 (GSD-1), 2 of whom were receiving granulocyte colony stimulating factor (G-CSF) therapy for chronic neutropenia. Patients were short (median height SD score -1.35, range -3.74 to -0.27), and had reduced BMC Z scores (median 1.79, range -6.35 to +0.27) and radial bone width Z scores (median -0.72, range -2.00 to +0.68). Those receiving G-CSF did not differ significantly from the rest of the group. Generally dietary calcium intake was low and urinary calcium excretion increased. Urinary lactate excretion was high but did not correlate with BMC Z scores. Factors regulating bone metabolism (parathyroid hormone and 25-hydroxy vitamin D concentrations) and markers of bone formation (osteocalcin and skeletal alkaline phosphatase) were not increased implying that there was no compensation for increased bone resorption.
CONCLUSION: Patients with GSD-1 may be at increased risk of fracture in later life and require close attention to metabolic control and calcium balance.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7545579     DOI: 10.1007/bf02029361

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  21 in total

Review 1.  Pathophysiology and dietary treatment of the glycogen storage diseases.

Authors:  S W Moses
Journal:  J Pediatr Gastroenterol Nutr       Date:  1990-08       Impact factor: 2.839

2.  Skeletal growth in school children: maturation and bone mass.

Authors:  R B Mazess; J R Cameron
Journal:  Am J Phys Anthropol       Date:  1971-11       Impact factor: 2.868

3.  Bone, acid, and osteoporosis.

Authors:  J A Kraut; J W Coburn
Journal:  N Engl J Med       Date:  1994-06-23       Impact factor: 91.245

4.  Comparison of the effects of total parenteral nutrition, continuous intragastric feeding, and portacaval shunt on a patient with type I glycogen storage disease.

Authors:  I M Burr; J A O'Neill; D T Karzon; L J Howard; H L Greene
Journal:  J Pediatr       Date:  1974-12       Impact factor: 4.406

5.  Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. I.

Authors:  J M Tanner; R H Whitehouse; M Takaishi
Journal:  Arch Dis Child       Date:  1966-10       Impact factor: 3.791

6.  Bone growth and mineralisation in children aged 4 to 10 years.

Authors:  J A DePriester; T J Cole; N J Bishop
Journal:  Bone Miner       Date:  1991-01

7.  Granulocyte and granulocyte-macrophage colony-stimulating factors for treatment of neutropenia in glycogen storage disease type Ib.

Authors:  H Schroten; J Roesler; T Breidenbach; U Wendel; J Elsner; S Schweitzer; C Zeidler; S Burdach; M L Lohmann-Matthes; V Wahn
Journal:  J Pediatr       Date:  1991-11       Impact factor: 4.406

8.  Bone mineral status in childhood accidental fractures.

Authors:  G M Chan; M Hess; J Hollis; L S Book
Journal:  Am J Dis Child       Date:  1984-06

9.  Infectious and bleeding complications in patients with glycogenosis Ib.

Authors:  D R Ambruso; E R McCabe; D Anderson; A Beaudet; L M Ballas; I K Brandt; B Brown; R Coleman; D B Dunger; J M Falletta
Journal:  Am J Dis Child       Date:  1985-07

10.  Inflammatory bowel disease in glycogen storage disease type Ib.

Authors:  T F Roe; D W Thomas; V Gilsanz; H Isaacs; J B Atkinson
Journal:  J Pediatr       Date:  1986-07       Impact factor: 4.406

View more
  10 in total

Review 1.  Dietary dilemmas in the management of glycogen storage disease type I.

Authors:  Kaustuv Bhattacharya
Journal:  J Inherit Metab Dis       Date:  2011-04-14       Impact factor: 4.982

2.  Bone mineral density and markers of bone turnover in patients with glycogen storage disease types I, III and IX.

Authors:  J Cabrera-Abreu; N J Crabtree; E Elias; W Fraser; R Cramb; S Alger
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

3.  A high activity index of stearoyl-CoA desaturase is associated with increased risk of fracture in men.

Authors:  H Melhus; U Risérus; E Warensjö; L Wernroth; K Jensevik; L Berglund; B Vessby; K Michaëlsson
Journal:  Osteoporos Int       Date:  2007-12-08       Impact factor: 4.507

4.  A novel starch for the treatment of glycogen storage diseases.

Authors:  K Bhattacharya; R C Orton; X Qi; H Mundy; D W Morley; M P Champion; S Eaton; R F Tester; P J Lee
Journal:  J Inherit Metab Dis       Date:  2007-05-19       Impact factor: 4.982

5.  Reduction in bone mineral density in glycogenosis type III may be due to a mixed muscle and bone deficit.

Authors:  H R Mundy; J E Williams; P J Lee; M S Fewtrell
Journal:  J Inherit Metab Dis       Date:  2008-04-04       Impact factor: 4.982

Review 6.  Investigation and management of the hepatic glycogen storage diseases.

Authors:  Kaustuv Bhattacharya
Journal:  Transl Pediatr       Date:  2015-07

Review 7.  Glucose-6-phosphatase deficiency.

Authors:  Roseline Froissart; Monique Piraud; Alix Mollet Boudjemline; Christine Vianey-Saban; François Petit; Aurélie Hubert-Buron; Pascale Trioche Eberschweiler; Vincent Gajdos; Philippe Labrune
Journal:  Orphanet J Rare Dis       Date:  2011-05-20       Impact factor: 4.123

8.  Bone mineral density in glycogen storage disease type Ia and Ib.

Authors:  Laurie A Minarich; Alexander Kirpich; Laurie M Fiske; David A Weinstein
Journal:  Genet Med       Date:  2012-04-05       Impact factor: 8.822

9.  Bone mineral density in children, adolescents and adults with glycogen storage disease type Ia: a cross-sectional and longitudinal study.

Authors:  J P Rake; G Visser; D Huismans; S Huitema; E van der Veer; D A Piers; G P A Smit
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.750

Review 10.  Bone health in patients with inborn errors of metabolism.

Authors:  M Langeveld; C E M Hollak
Journal:  Rev Endocr Metab Disord       Date:  2018-03       Impact factor: 6.514

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.